Health
FDA OKs limited use of Tysabri
NEWS IN BRIEF — Posted June 26, 2006
The Food and Drug Administration decided June 5 to allow Tysabri (natalizumab) to be prescribed once more, although this time with numerous restrictions. The drug had been approved in November 2004 for patients with relapsing forms of multiple sclerosis but was removed from the market in February 2005 by its manufacturer after three patients in the drug's clinical trials developed a serious brain infection -- two died as a result.
The drug, a monoclonal antibody, had been hailed as an important new treatment.
Under the new prescribing restrictions, Tysabri is to be used alone rather than in combination with other immune-system-modifying drugs and only for patients who have not responded adequately to, or cannot tolerate, other treatments for MS.
In addition, the FDA is adopting a requirement recommended by its Peripheral and Central Nervous System Drugs Advisory Committee that there be mandatory patient registration and periodic follow-up to identify as early as possible any cases of progressive multifocal leukoencephalopathy, or PML, that may occur and to try to determine the reason for the infection.
Prescribers, pharmacies and infusion centers who handle the drug also will have to register with the risk management plan, called the TOUCH Prescribing Program, developed by manufacturer Biogen Idec. Before initiating the therapy, patients must have an MRI scan to help differentiate potential future multiple sclerosis symptoms from PML.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/06/26/hlbf0626.htm.












